Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 10/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.38 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899437 | 0.82 | RAB9A (0.49) | SYKRAB9ASRCZAP70CDK2 | |
| SCHEMBL4900811 | 0.80 | SYK (0.40) | SYKRAB9ASRCZAP70CDK2 | |
| SCHEMBL4904404 | 0.80 | PDPK1 (0.45) | SYKRAB9ASRCZAP70CDK2 | |
| SCHEMBL4899975 | 0.79 | RAB9A (0.40) | SYKRAB9ASRCZAP70CDK2 | |
| SCHEMBL4896690 | 0.79 | SYK (0.49) | SYKRAB9ASRCZAP70CDK2 | |
| SCHEMBL4899942 | 0.79 | LYN (0.49) | SYKRAB9ASRCZAP70CDK2 | |
| SCHEMBL27682393 | 0.79 | RAB9A (0.40) | SYKRAB9ASRCZAP70CDK2 | |
| SCHEMBL4901358 | 0.79 | SLC2A1 (0.49) | SYKRAB9ASRCZAP70CDK2 | |
| SCHEMBL4899241 | 0.79 | CYP1A1 (0.48) | SYKRAB9ASRCZAP70CDK2 | |
| Hydrochloric Acid SCHEMBL4902556 | 0.79 | PDPK1 (0.44) | SYKRAB9ASRCZAP70CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | ICAGEN, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1737852-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100349-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | KCNJ2, KCNH2, KCNQ1 | SYK 4140/4885RAB9A 3132/4885CHEK1 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.